Back to results
US 2021/0260082 A1Published application
Phosphinic amide prodrugs of tenofovir
AssigneeMerck Sharp & Dohme Corp.
InventorsManuel De Lera Ruiz, Izzat Raheem, Michael T. Rudd
Life of this patent
Estimating the term…
Abstract
Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
Claims19
A compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is (a) —C1-4alkyl, (b) —C1-4alkyl substituted with —OH, —SH, —SCH3, —NH2, —NH—C(═NH)—NH2, (c) —CH2-phenyl, (d) —CH2-phenol, (e) —(CH2)1-2—COOH, (f) —(CH2)1-2—CONH2, (g) —CH2-1H-indole, (h) —CH2-imidazole, (i) aryl or (j) heteroaryl;
- —R2 is (a) —C1-4alkyl, (b) —C1-4alkyl substituted with —OH, —SH, —SCH3, —NH2, —NH—C(═NH)—NH2, (c) —CH2-phenyl, (d) —CH2-phenol, (e) —(CH2)1-2—COOH, (f) —(CH2)1-2—CONH2, (g) —CH2-1H-indole, (h) —CH2-imidazole, (i) aryl or (j) heteroaryl;
- or R1 and R2 are joined together with the carbon to which they are both attached to form —C3-6cycloalkyl or a 4 to 6-membered heterocyclic ring;
- R3 is —CN, —CF3, phenyl, heteroaryl, —C(O)OR5b, —C(O)—N(R6a)(R6b), —S(O)2R5b or —S(O)2—N(R6a)(R6b) wherein each of phenyl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected at each occurrence from R10;
- R4 is —H, —CN, —CF3, phenyl, heteroaryl, —C(O)OR5c or —C(O)—N(R6c)(R6d), —S(O)2R5c or —S(O)2—N(R6c)(R6d) wherein each of phenyl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected at each occurrence from R10;
- R5a, R5b and R5c are each independently:
- (a) —C1-10alkyl unsubstituted or substituted with one to three substituents, wherein each substituent is independently fluoro, chloro, bromo, —CN, —CF3, —NR7aR7b, —OR8, —SH, —C3-6cycloalkyl or spiro-C3-6cycloalkyl,
- (b) —CH2-phenyl unsubstituted or substituted with one to three substituents, wherein each substituent is independently selected at each occurrence from R10,
- (c) —C3-8 cycloalkyl unsubstituted or substituted with one to three substituents, wherein each substituent is independently selected at each occurrence from R10,
- (d) aryl unsubstituted or substituted with one to three substituents, wherein each substituent is independently selected at each occurrence from R10,
- (e) —C1-5alkyl-X—C1-5alkyl wherein X is O, S or NH,
- (f) heteroaryl unsubstituted or substituted with one to three substituents, wherein each substituent is independently selected at each occurrence from R10, or
- (g) a heterocyclic ring unsubstituted or substituted with one to three substituents, wherein each substituent is independently selected at each occurrence from R10;
- R6a, R6b, R6c and R6d are each independently —H, —C1-3alkyl or —C3-6cycloalkyl;
- R7a and R7b are each independently —H, —C1-3alkyl or —C3-6cycloalkyl;
- R8 is —H or —C3-6cycloalkyl;
- and
- R9 is —H, —C1-3alkyl or —C3-6cycloalkyl;
- and
- R10 is fluoro, chloro, bromo, —CN, —CF3, —NR7aR7b, —OR9, —SH or —C1-3alkyl.
18 more elements
19-21. (canceled)
Dependencies are inferred from the claim text.